Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 28, 2017; 23(44): 7899-7905
Published online Nov 28, 2017. doi: 10.3748/wjg.v23.i44.7899
Published online Nov 28, 2017. doi: 10.3748/wjg.v23.i44.7899
Table 1 Baseline characteristics of the patients
| Characteristics | Value |
| Total participants (n) | 1375 |
| mean age (yr) mean ± SD (range) | 48 ± 13 (18-65) |
| Gender | |
| Male | 696 (50.62%) |
| Female | 679 (49.38%) |
| Treatment history | |
| Treatment naive | 490 (35.64%) |
| Treatment experienced | 885 (64.36%) |
| Laboratory investigations | |
| Hemoglobin(Hb) (g/dL), mean ± SD (range) | 12.50 ± 3.50 (7.5-18.3) |
| Platelets (103/μL), mean ± SD (range) | 160 ± 76 (50-450) |
| Creatinine (mg/dL) | 0.65 ± 0.22 (0.38-1.50) |
| Mean viral load (106 IU/mL) mean ± SD (range) | 3.54 ±2.56 (0.01-33.98) |
| HCV genotype 3 | 1375 (100%) |
Table 2 Association of baseline characteristics of the patients with sustained virological response treated with sofosbuvir+ribavirin (First group) n (%)
| Baseline characteristics (n = 847) | ETR (n = 847), overall ETR = 100% | SVR (n = 840), overall SVR = 99.17% | Relapse (n = 7), overall relapse rate = 0.83% |
| Age (yr) | |||
| ≤ 40 (n = 435) | 435 (100) | 433 (99.54) | 2 (0.46) |
| > 40 (n = 412) | 412 (100) | 407 (98.79) | 5 (1.21) |
| Previous antiviral treatment history | |||
| Naïve (n = 91) | 91(100) | 89 (97.80) | 2 (2.20) |
| Treated (n = 756) | 756 (100) | 751 (99.34) | 5 (0.66) |
| Gender | |||
| Male (n = 310) | 310 (100) | 309 (99.68) | 1 (0.32) |
| Female (n = 537) | 537 (100) | 531 (98.88) | 6 (1.12) |
Table 3 Association of baseline characteristics of the patients with sustained virological response treated with sofosbuvir+ribavirin+peg-interferon alfa-2a (Second group) n (%)
| Baseline characteristics (n = 528) | ETR (n = 526), overall ETR 0.9962 | SVR (n = 515), overall SVR 0.9791 | Relapse (n = 11), overall relapse rate = 2.09% |
| Age (yr) | |||
| ≤ 40 (n = 419) | 419 (100) | 415 (99.05) | 4 (0.95) |
| > 40 (n = 109) | 107 (98.17) | 100 (93.46) | 7 (6.54) |
| Previous antiviral treatment history | |||
| Naïve (n = 399) | 399 (100) | 396 (99.25) | 3 (0.75) |
| Treated (n = 129) | 127 (98.45) | 119 (93.70) | 8 (6.30) |
| Gender | |||
| Male (n = 386) | 386 (100) | 382 (98.96) | 4 (1.04) |
| Female (n = 142) | 140 (98.59) | 133 (95) | 7 (5) |
Table 4 Association of baseline characteristics of the patients with sustained virological response treated with sofosbuvir+ribavirin (First group) n (%)
| Time point | Viral load (n = 847) | ETR (n = 847), overall ETR =100% | SVR (n = 840), overall SVR = 99.17% | Relapse (n = 7), overall relapse rate = 0.83% |
| Baseline (d-0) | ≤ 2 MIU/mL (n = 630) | 630 (100) | 628 (99.68) | 2 (0.32) |
| > 2 MIU/mL (n = 217) | 217 (100) | 212 (97.70) | 5 (2.30) | |
| RVR (weeks-4) | Negative (n = 290) | 290 (100) | 290 (100) | 0 (0) |
| ≥ 2 log drop (n = 540) | 540 (100) | 539 (99.81) | 1 (0.19) | |
| < 2 log drop (n = 17) | 17 (100) | 11 (64.70) | 6 (35.30) |
Table 5 Association of baseline characteristics of the patients with sustained virological response treated with sofosbuvir + ribavirin + peg-interferon-alfa-2a (Second group) n (%)
| Time point | Viral load (n = 528) | ETR (n = 526), overall ETR 0.9962 | SVR (n = 515), overall SVR 0.9791 | Relapse (n = 11), overall relapse rate = 2.09% |
| Baseline (d-0) | ≤ 2 MIU/mL (n = 316) | 316 (100) | 313 (99.05) | 3 (0.95) |
| > 2 MIU/mL (n = 212) | 210 (99.06) | 202 (96.19) | 8 (3.81) | |
| RVR (weeks-4) | Negative (n = 116) | 116 (100) | 116 (100) | 0 (0) |
| ≥ 2 log drop (n = 380) | 380 (100) | 376 (98.95) | 4 (1.05) | |
| < 2 log drop (n = 32) | 30 (93.75) | 23 (76.67) | 7 (23.33) |
Table 6 Side effects (n = 1375) n (%)
| Side effects | SOF + RBV (n = 847) | SOF + RBV + Peg (n = 528) | P value |
| Headache | 248 (29.28) | 198 (37.50) | 0.083 |
| Fatigue | 147 (17.36) | 168 (31.82) | 0.001 |
| Myalgia | 38 (4.49) | 43 (8.14) | 0.830 |
| Hashimoto's thyroiditis | 2 (0.23) | 1 (0.19) | 0.001 |
| Decreased appetite | 71 (8.38) | 89 (16.86) | 0.179 |
| Rash | 7 (0.82) | 3 (0.57) | 0.001 |
| Thrush | 23 (2.71) | 19 (3.60) | 0.467 |
| Hair loss | 8 (0.94) | 59 (11.17) | 0.781 |
| Aggressiveness | 29 (3.42) | 38 (7.20) | 0.895 |
| Pruritus | 69 (8.14) | 57 (10.79) | 0.959 |
| Insomnia | 79 (9.32) | 63 (11.93) | 0.498 |
| Depression | 36 (4.25) | 67 (12.69) | 0.006 |
| Acute psychosis | 8 (0.94) | 3 (0.57) | 0.776 |
| Hematologic abnormalities | |||
| Anemia (< 10 g/dL) | 238 (28.10) | 215 (40.72) | 0.001 |
| Leukocytopenia (< 3 × 103/μL) | 16 (1.89) | 61 (11.55) | 0.001 |
| Thrombocytopenia (< 100 × 103/μL) | 64 (7.56) | 72 (13.64) | 0.188 |
| Bell’s Palsy | 3 (0.35) | 1 (0.19) | 0.628 |
| Intracranial hemorrhage | 2 (0.23) | 0 (0) |
- Citation: Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol 2017; 23(44): 7899-7905
- URL: https://www.wjgnet.com/1007-9327/full/v23/i44/7899.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i44.7899